Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Cancer Research
|
April 1, 1993
In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes
Y H Ling, W Priebe, L Y Yang, et al.
Journal of Medicinal Chemistry
|
January 31, 1997
Structure-based design of a new bisintercalating anthracycline antibiotic
J B Chaires, F Leng, T Przewloka, et al.
Current Medicinal Chemistry
|
February 15, 2001
Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action
A Garnier-Suillerot, C Marbeuf-Gueye, M Salerno, et al.
Blood
|
July 15, 1996
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines
U Consoli, W Priebe, Y H Ling, et al.
International Journal of Cancer
|
March 28, 1997
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide
R Perez-Soler, N Neamati, Y Zou, et al.
Biochemistry
|
March 4, 1997
Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge
T J Lampidis, D Kolonias, T Podona, et al.
Cancer Chemotherapy and Pharmacology
|
December 29, 2000
Phase I study of liposomal annamycin
D J Booser, R Perez-Soler, P Cossum, et al.
Antimicrobial Agents and Chemotherapy
|
April 24, 2004
Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription
Olaf Kutsch, David N Levy, Paula J Bates, et al.
International Journal of Molecular Sciences
|
January 8, 2020
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents
B Pajak, E Siwiak, M Sołtyka, et al.
Anticancer Research
|
March 26, 2002
WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity
S Faderl, Z Estrov, H M Kantarjian, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Cancer Research
|
April 1, 1993
In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes
Y H Ling, W Priebe, L Y Yang, et al.
Journal of Medicinal Chemistry
|
January 31, 1997
Structure-based design of a new bisintercalating anthracycline antibiotic
J B Chaires, F Leng, T Przewloka, et al.
Current Medicinal Chemistry
|
February 15, 2001
Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action
A Garnier-Suillerot, C Marbeuf-Gueye, M Salerno, et al.
Blood
|
July 15, 1996
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines
U Consoli, W Priebe, Y H Ling, et al.
International Journal of Cancer
|
March 28, 1997
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide
R Perez-Soler, N Neamati, Y Zou, et al.
Biochemistry
|
March 4, 1997
Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge
T J Lampidis, D Kolonias, T Podona, et al.
Cancer Chemotherapy and Pharmacology
|
December 29, 2000
Phase I study of liposomal annamycin
D J Booser, R Perez-Soler, P Cossum, et al.
Antimicrobial Agents and Chemotherapy
|
April 24, 2004
Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription
Olaf Kutsch, David N Levy, Paula J Bates, et al.
International Journal of Molecular Sciences
|
January 8, 2020
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents
B Pajak, E Siwiak, M Sołtyka, et al.
Anticancer Research
|
March 26, 2002
WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity
S Faderl, Z Estrov, H M Kantarjian, et al.
Page
of 9